Jefferies downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy with a price target of 50c, down from $5. The company’s Phase III study of oral ganaxolone in tuberous sclerosis complex rare-epilepsy failed to meet the primary endpoint of seizure reduction, the analyst tells investors in a research note. The firm sees no near-term catalysts in 2025, driving the downgrade to Hold.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities
- Marinus downgraded to Market Perform from Outperform at JMP Securities
- Marinus Pharmaceuticals downgraded to Hold from Buy at Truist